Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Whether it's wooing investors, building a patent portfolio, critiquing multinational pharmaceutical firms or tackling hereditary diseases in her native community, Avesthagen CEO Villoo Morawala Patell brings a unique mix of dynamism and intellectual verve to the table.
FDA left no doubt after a May meeting that it plans to continue pressuring sponsors of erythropoiesis-stimulating agents for more definitive clinical data.
The next wave of protein therapeutics, based on non-traditional scaffolds, may offer advantages in the range of conditions they can treat, delivery, and manufacturing. But they are just beginning to prove themselves in the clinic.
The UK's Office of Fair Trading is suggesting a system of drug pricing based on therapeutic value, which it believes would better focus innovation and investment toward creating more valuable drugs.